Search company, investor...
Invivyd company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Invivyd

Invivyd (NASDAQ: IVVD), formerly known as Adagio Therapeutics (NASDAQ: ADGI), develops antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses. The company was founded in 2020 and is based in Waltham, Massachusetts.

Invivyd Headquarters Location

1601 Trapelo Road Suite 178

Waltham, Massachusetts, 02451,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Invivyd

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Invivyd in 1 CB Insights research brief, most recently on Aug 5, 2021.

Expert Collections containing Invivyd

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Invivyd is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Invivyd Patents

Invivyd has filed 4 patents.

The 3 most popular patent topics include:

  • Animal virology
  • Clusters of differentiation
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Animal virology, Proteins, Immunology, Human proteins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Animal virology, Proteins, Immunology, Human proteins



Latest Invivyd News

Sept. 12 Quick Takes: Nimbus draws $125M to advance pair of lead molecules

Sep 13, 2022

Sept. 12 Quick Takes: Nimbus draws $125M to advance pair of lead molecules Plus new name, COVID-19 mAb for Adagio and updates from Horizon, Acadia, Chiesi and more By BioCentury Staff September 13, 2022 12:56 AM UTC Two years after raising a $60 million crossover round, Nimbus Therapeutics LLC has turned to Bain Capital Life Sciences and SV Health Investors to lead a new $125 million private financing. The 13-year-old computational chemistry company, which launched with an asset-focused, partnership-heavy strategy but has increasingly focused on its internal pipeline in recent years, is conducting Phase IIb trials of allosteric TYK2 inhibitor NDI-034858 to treat psoriatic arthritis and psoriasis, and Phase I/II testing of HPK1 inhibitor to treat solid tumors. A little more than two years after being spun out of Adimab LLC to develop mAbs to treat COVID-19, Adagio Therapeutics Inc. (NASDAQ:ADGI) is changing its name to Invivyd and will trade under the IVVD ticker symbol starting Tuesday. The biotech raised $825 million in just over a one-year span, including a $355.8 million IPO in August 2021, before the stock sank more than 80% last December after the company reported its lead COVID-19 mAb ADG20 showed a more than 300-fold reduction in neutralizing activity against the Omicron variant, a reversal from prior claims that the mAb was active against the strain. Separately on Monday, Invivyd said it selected NVD200, a combination of two mAbs, as its next lead candidate against COVID-19, with plans to enter the clinic in 1Q23. Invivyd had a market cap of $500 million on Monday and had reported $475 million in cash at June 30... BCIQ Company Profiles

Invivyd Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Invivyd Rank

  • When was Invivyd founded?

    Invivyd was founded in 2020.

  • Where is Invivyd's headquarters?

    Invivyd's headquarters is located at 1601 Trapelo Road, Waltham.

  • What is Invivyd's latest funding round?

    Invivyd's latest funding round is IPO.

  • How much did Invivyd raise?

    Invivyd raised a total of $466M.

  • Who are the investors of Invivyd?

    Investors of Invivyd include OrbiMed Advisors, Mithril Capital Management, Polaris Partners, Fidelity Investments, Google Ventures and 13 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.